Form SC 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001087294-14-000003
Filing Date
2014-02-14
Accepted
2014-02-14 17:01:09
Documents
1

Document Format Files

Seq Description Document Type Size
1 SC 13G schedule13g-ajkazimi2013.htm SC 13G 76425
  Complete submission text file 0001087294-14-000003.txt   77920
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filed by) CIK: 0001087294 (see all company filings)

EIN.: 000000000
Type: SC 13G
SIC: 2834 Pharmaceutical Preparations

Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Subject) CIK: 0001087294 (see all company filings)

EIN.: 000000000
Type: SC 13G | Act: 34 | File No.: 005-85205 | Film No.: 14618259
SIC: 2834 Pharmaceutical Preparations